CMV Retinitis: Clinical Experience with the Metal Chelator Desferrioxamine

[1]  M. Jacobson,et al.  Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. , 1997, The New England journal of medicine.

[2]  R. Dix,et al.  Systemic cytokine immunotherapy for experimental cytomegalovirus retinitis in mice with retrovirus-induced immunodeficiency. , 1997, Investigative ophthalmology & visual science.

[3]  B. Markus,et al.  Immunomodulatory properties of the metal chelators desferrioxamine and diethylenetriamine penta-acetic acid in vitro. , 1996, Transplantation.

[4]  B. Sha.  Combination Foscarnet and Ganciclovir Therapy vs. Monotherapy for the Treatment of Relapsed Cytomegalovirus Retinitis in Patients with AIDS: The Cytomegalovirus Retreatment Trial , 1996, Archives of ophthalmology.

[5]  F. Baldanti,et al.  Single amino acid changes in the DNA polymerase confer foscarnet resistance and slow-growth phenotype, while mutations in the UL97-encoded phosphotransferase confer ganciclovir resistance in three double-resistant human cytomegalovirus strains recovered from patients with AIDS , 1996, Journal of virology.

[6]  S. Chou,et al.  Frequency of UL97 phosphotransferase mutations related to ganciclovir resistance in clinical cytomegalovirus isolates. , 1995, The Journal of infectious diseases.

[7]  B. Markus,et al.  Effects of desferrioxamine on human cytomegalovirus replication and expression of HLA antigens and adhesion molecules in human vascular endothelial cells. , 1995, Transplant immunology.

[8]  H. Doerr,et al.  In vitro inhibition of human cytomegalovirus replication by desferrioxamine. , 1994, Antiviral research.

[9]  P. Rebulla,et al.  Incidence of AIDS in HIV‐1 infected thalassaemia patients , 1992, British journal of haematology.

[10]  A. Hoffbrand,et al.  Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPA. , 1989, Archives of disease in childhood.

[11]  J. Bartlett,et al.  Cytomegalovirus retinitis and acquired immunodeficiency syndrome. , 1989, Archives of ophthalmology.

[12]  S. Weller,et al.  Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: isolation and characterization of an ICP6 lacZ insertion mutant , 1988, Journal of virology.

[13]  A. Rahi,et al.  Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findings. , 1986, The British journal of ophthalmology.

[14]  R D Yee,et al.  Acquired immune deficiency syndrome. Ocular manifestations. , 1983, Ophthalmology (Rochester, Minn.).

[15]  T. Merigan,et al.  Cytomegalovirus retinitis in immunosuppressed hosts. I. Natural history and effects of treatment with adenine arabinoside. , 1980, Annals of internal medicine.

[16]  D. Nicholson.  Cytomegalovirus Infection of the Retina , 1975, International ophthalmology clinics.